rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

The Hemophilia Inhibitor Prevention Trial

NCT04303559 ·Status: TERMINATED ·Phase: PHASE3

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

NCT03093480 ·Status: COMPLETED ·Phase: PHASE4

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4

Epidemiology and Immunology of Hemophilia A Inhibitors

NCT00005518 ·Status: COMPLETED

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)

NCT01051076 ·Status: COMPLETED ·Phase: NA

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

NCT03588741 ·Status: TERMINATED ·Phase: PHASE3

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

NCT01125813 ·Status: COMPLETED ·Phase: PHASE3

Study Evaluating ReFacto in Hemophilia A

NCT00038909 ·Status: COMPLETED ·Phase: NA

Study Evaluating ReFacto AF in Severe Hemophilia A

NCT00037544 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

NCT02035384 ·Status: COMPLETED

Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients

NCT02479087 ·Status: UNKNOWN ·Phase: PHASE4

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

NCT03191799 ·Status: COMPLETED ·Phase: PHASE3

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

NCT01863758 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Hemophilia A Patients With FVIII Inhibitors

NCT04023019 ·Status: RECRUITING

Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A

NCT00038935 ·Status: COMPLETED ·Phase: PHASE3

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

NCT00323856 ·Status: COMPLETED ·Phase: PHASE4

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934 ·Status: ACTIVE_NOT_RECRUITING

Rituximab to Treat Severe Hemophilia A

NCT00331006 ·Status: COMPLETED ·Phase: PHASE2

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive

NCT01051544 ·Status: WITHDRAWN ·Phase: NA

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

NCT02256917 ·Status: COMPLETED ·Phase: PHASE3

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

NCT06137092 ·Status: COMPLETED ·Phase: PHASE3

PF-06741086 Long-term Treatment in Severe Hemophilia

NCT03363321 ·Status: COMPLETED ·Phase: PHASE2

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830 ·Status: RECRUITING ·Phase: PHASE4

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

NCT00168051 ·Status: WITHDRAWN ·Phase: PHASE4

Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa

NCT01856751 ·Status: UNKNOWN